Uric acid lowering therapy in cardiovascular diseases

详细信息    查看全文

• 作者：Maurizio Volterrani^a ; ^{maurizio.volterrani@sanraffaele.it" class="auth_mail" title="E-mail the corresponding author} ; Ferdinando Iellamo^b ; Barbara Sposato^a ; Franco Romeo^c
• 关键词：Uric acid ; Cardiovascular diseases ; Xanthine oxidase activity ; Xanthine oxidase inhibition
• 刊名：International Journal of Cardiology
• 出版年：2016
• 出版时间：15 June 2016
• 年：2016
• 卷：213
• 期：Complete
• 页码：20-22
• 全文大小：224 K

文摘

Recent evidence would indicate that high serum uric acid (SUA) levels can be a significant and independent risk factor for hypertension and cardiovascular diseases, such as ischemic heart disease and heart failure. In the last few years an independent risk relationship between hyperuricemia, cardiovascular disease and mortality has also been reported. Hyperuricemia has been shown as an independent risk factor for acute myocardial infarction and an independent and conjoint association of either gout and SUA with total and cardiovascular mortality has been reported, with mortality impact in gout patients increasing with rising SUA concentrations, even for SUA levels in the normal to high range. These findings prompted a growing research interest on the possible benefits of uric acid lowering drugs in cardiovascular diseases. Indeed, clinical studies have reported on the beneficial effects of uric acid lowering drugs, in particular of xanthine oxidase inhibitors, in hypertension, ischemic heart disease and heart failure. Two main mechanisms have been claimed to explain the dangerous effects of hyperuricemia and, as a consequence, the benefits of uric acid lowering therapy: endothelial dysfunction and systemic inflammation.

This brief review aims to summarize current evidence from human studies on the role of acid uric lowering therapy in cardiovascular diseases for practical and clinical purposes. The possible mechanisms underlying the benefits of acid uric lowering therapy are also addressed.